Redefining Healing
Through Science

Passionate Pioneers
of Healing Innovations

Determined to make a difference in the world, our founder set out on a mission to develop the science behind better healing. Today, that same passion drives us forward—redefining healing and transforming lives through science, innovation, and unwavering commitment.

molecule-close-up
microscope-close-up
xperience-200k-statistic

Empowering Physicians, Improving Outcomes, and Advancing Healthcare

We deeply value the physician-patient connection and its life-changing impact through healthy healing. Our pursuit is to enhance patient outcomes, empower physicians, and drive healthcare innovation through education, research, and cutting-edge product development.

Who We Are

From Garage Experiments to Lifesaving Innovation

The medical technology world is filled with stories of breakthrough innovation driven by big companies in fancy laboratories, but not at Next Science. Our story begins in Dr. Matthew (“Matt”) Myntti’s garage.

A materials science engineering Ph.D., Matt established himself as a research & development pioneer and industry expert while working at a large, global medical device company. Frustrated over the lack of treatments for the wildly common problem of bacterial infections leading to patient suffering, Matt started growing bacteria and experimenting in his garage in his free time. Surely he could use his science smarts (aka advanced knowledge of the principles of chemistry, molecular biology, and materials properties) to develop something – anything – to help.

And in 2012, Next Science was born. Matt took the leap out of corporate America, committed to tackling one of the leading causes of antimicrobial resistance, bacterial biofilms, in the name of helping people. 78 patents later, Matt continues to pour his heart and soul into serving others by continuing his personal war against bacteria & biofilm – a quest to prevent infection and treat inflammatory disease.

Matt is also thrilled to be able to park his car in the garage again.

Our Vision

Healing People and Saving Lives

Our Mission

Driving Better Outcomes Through Relentless Innovation

Next Science strives to significantly improve patient outcomes, elevate physician efficacy, and create value within the overall healthcare system through relentless innovation and commitment to education and research on biofilm elimination, infection prevention, and treatments for inflammatory diseases.

Our Core Values

Because Integrity, Quality & Collaboration Are Table Stakes

01

icon-hand
Service with heart — for patients, people, and purpose beyond ourselves.

02

icon-magnifying_glass
Curiosity about people, ideas, and what’s possible.


03

icon-climber
Progress fueled by courage, drive by speed — we execute with urgency to shape what’s NEXT.

Our Leadership

Many Minds, One Focus

With diverse, proven experience in research and development and bringing innovative technologies to market, our team has championed medtech innovation through the years. We are committed to improving public health through groundbreaking and invaluable solutions backed by the latest in scientific research and discovery.

The Next Science Leadership Team

Harry Thomas Hall IV, known as I.V., is the current Managing Director/Chief Executive Officer of Next Science. I.V. has more than 28 years in the global medical device industry and has held diverse general management roles including product development, global strategic marketing, commercial operations, and sales leadership. His diverse background and profound understanding of the industry make him the perfect fit to lead Next Science into the future.

I.V. holds a Bachelor of Science: Ceramic Engineering and Master of Science: Bioengineering from Clemson University, as well as an MBA from Pennsylvania State University. I.V. also completed the Advanced Management Program at Harvard Business School.

As the founder and CTO of Next Science, Dr. Matt Myntti oversees and manages all aspects of R&D and product ideation of Next Science technologies. He received his Master’s and Doctoral degrees in Materials Science and Engineering from the University of Dayton and has over 30 granted US patents. Dr. Myntti previously led the biomaterials group at Medtronic Surgical Technologies, which developed novel ENT and neurologic products.

Currently serving as Chief Strategy Officer, Jon Swanson joined the Next Science team in June 2018 as the Chief Operating Officer to lead the operations, quality and regulatory teams. Mr. Swanson joins us from McKinsey & Co., where as the Head of the Advanced Operations Group, he focused on client operational improvement, product development and quality performance for pharma and medical product industries since 2011.

Prior to that, Mr. Swanson spearheaded manufacturing, product development and operational excellence at Medtronic in multiple leadership roles. As a professional rooted in operations and nuclear engineering excellence, he started his career in the US Navy. He holds a Master’s Degree in Business Administration from the University of Florida and a Bachelor’s Degree in Mathematics from the US Naval Academy.

Marc Zimmerman is the Chief Financial Officer at Next Science. After a 16-year career at Verizon Wireless, which included roles as Vice President of Supply Chain for the Wireless operation, Master Black Belt in the Lean Six Sigma program, and Area CFO for the Northeast Area, he joined Actavo, headquartered in Dublin, Ireland, as the CFO for the US and Caribbean operation. Most recently, he was the CFO for Center for Transportation and the Environment.

Mr. Daniel Canon is the VP, Operations at Next Science. As the former Senior Engineering Manager at Medtronic, he managed strategic company acquisitions, development and execution of subsequent business integration strategies to assure top notch medical device production quality.

An industry veteran with over 20 years of experience, Mr. Canon has lead complex projects in military, commercial, defense and medical operational environments. He has a Bachelor’s Degree in Electrical Engineering from Pennsylvania State University and a Master’s Degree in Mechanical Engineering from the University of Maryland.

Jeanne Lee is the Vice President of Quality, Regulatory Affairs, and Clinical Operations at Next Science. Ms. Lee brings over 20 years of global regulatory experience within the medical device and pharmaceutical industries, gained at leading companies including Hollister Incorporated, Abbott Laboratories and Merck & Co. Inc. Ms. Lee holds a Master of Science degree in Regulatory Affairs and Quality Assurance from Temple University.

Robert “Rob” Bell is the Senior Vice President of Sales in North America for Next Science. Mr. Bell oversees the commercial operations via industry partners and direct sales channels in both the surgical and wound sectors. He is responsible for creating and implementing sales strategies, pursuing new business opportunities, and maintaining a strong sales pipeline and salesforce. Mr. Bell has held various leadership roles within orthopedics, establishing distribution and subsidiaries globally, bringing 14 years of experience in the Medical Device and Orthopedics industries.

Board of Directors

Sharing the same values and goals as everyone at Next Science, the Board of Directors is comprised of industry executives with the knowledge, expertise, and passion to help guide the company in fulfilling its mission.

Prior to joining Next Science, Aileen was the Worldwide Vice President of Business Development for the DePuy Synthes Group of Johnson & Johnson, where she oversaw the group’s merger and acquisition activities, including deal structuring, negotiations, contract design and review, and deal terms. She led Johnson & Johnson’s efforts to acquire Synthes for approximately $21 billion, Johnson & Johnson’s largest medical device acquisition. She also led the efforts to divest the DePuy Trauma business and acquire Micrus Endovascular. Aileen was also involved in numerous other M&A transactions including Pfizer Consumer Healthcare (US$16.5 billion), Aveeno, BabyCenter, OraPharma, DePuy, DePuy Miket, Kodak Clinical Diagnostics and Neutrogena. Aileen is a Non-Executive Director of Microbot Medical Inc. (NASDAQ: MBOT)

Harry Thomas Hall IV, known as I.V., is the current Managing Director/Chief Executive Officer of Next Science. I.V. has more than 28 years in the global medical device industry and has held diverse general management roles including product development, global strategic marketing, commercial operations, and sales leadership. His diverse background and profound understanding of the industry make him the perfect fit to lead Next Science into the future.

I.V. holds a Bachelor of Science: Ceramic Engineering and Master of Science: Bioengineering from Clemson University, as well as an MBA from Pennsylvania State University. I.V. also completed the Advanced Management Program at Harvard Business School.

Grant was part of Next Science’s ASX listing deal team in 2019. He has been a partner of a major Australian law firm for over fifteen years. Grant has experience with corporate and commercial transactions, with particular expertise in advising primary care, allied health, medical device and life science clients. Grant has been a non-executive director of GLG Corp Ltd (ASX:GLE)(GLG) since 2018 and serves as the Chair of GLG’s Nomination and Remuneration Committee and as a member of GLG’s Audit and Risk Committee. Grant holds a Bachelor of Science with an honours degree in molecular genetics and a Bachelor of Laws (Honours) from the University of Tasmania. Grant also has a Graduate Diploma of Applied Finance and Investment from FINSIA (now Kaplan).

Kathy is an experienced non-executive director and audit and risk committee chair. Kathy was an Audit, Assurance and Risk Consulting Partner at KPMG from 2005 to 2017 and has extensive experience in the aged care and healthcare sectors, having established and led KPMG’s New South Wales Health, Ageing and Human Services audit practice from 2006 to 2018. During her 24 years with KPMG, Kathy worked in Australia, the US, Asia, and the UK. Kathy currently serves as a Non-Executive Director of 3P Learning Limited (ASX:3PL), dusk Group Limited (ASX:DSK), Capral Limited (ASX:CAA) and Alex Corporation Limited. She holds a Bachelor of Commerce (Accounting and Finance) from the University of New South Wales and is a Fellow of the Financial Services Institute of Australasia. Ms Ostin is also a graduate of the Australian Institute of Company Directors.

Our Partners

A Partner of Choice

As we continue to pioneer and bring to market patented, break-through solutions, we also join forces with others to accelerate the adoption of proven solutions for addressing microbial burden.

Research Partners

Investigator-sponsored Research

Born from scientific research, we thrive on curiosity and collaboration to improve patient care and save lives. Our Investigator-sponsored Research program supports pioneering studies that address critical medical challenges and advance healing.

Investigator Application Requirements

We’re looking for investigators with expertise and experience in relevant medical fields, along with access to properly trained staff and facilities for conducting research.

All applicants must follow the appropriate guidelines and regulations, including:
  • Good Clinical Practice (GCP)
  • Good Documentation Practice (GDP)
  • Good Laboratory Practice (GLP) (if applicable)
What to Submit:
  • Completed Application
  • CV & Medical License Copies
Optional (but recommended):
  • Cover Letter (max 500 words)
  • Letter of Intent
  • List of Publications or Other Supporting Information to help us understand your research goals.

Both Next Science and applicants will comply with the Federal Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b)) and its regulations at all times.

Submit completed applications to [email protected]. Upon receipt, the proposal will be given a unique ID. Please retain this ID for your records.

Investor Centre

Notice

The Investor Centre website is wholly owned & managed by Next Science Ltd., an Australian publicly traded company (NSX:ASX) and parent company of Next Science, LLC. Please be aware terms of use, privacy policies, and data practices may differ.

Click here to continue to the Investor Centre website.

Advanced Wound Solutions

Our Products

XPERIENCE

BLASTX®

XPERIENCE Advanced Surgical Irrigation

FDA-Cleared. Doctor-Validated.
From clinics to hospitals, XPERIENCE is approved for use in 2000+ healthcare facilities across the U.S.*
  • Improve workflow, no saline rinse required.
  • Rinse away debris and microorganisms from wounds using a patented combination of ingredients.
Citric Acid Buffer Combines with sodium citrate to maintain an optimal pH.
Sodium Citrate Buffer Buffers solution to maintain the appropriate pH.
Sodium Lauryl Sulfate Surfactant Acts as surfactant to assist in solubilization of debris.
  • Can be used with manual or powered irrigation.
  • Biocompatible and safe for patients.
Tested by science. Trusted by clinicians. XPERIENCE has been trusted in the care of over 200,000 patients in the U.S.** View brochure View IFU View How to Spike Brochure
  • *Next Science national accounts information, 2025 data on file
  • ** Distribution records from 4/27/21-4/25/25

BLASTX®

ENGINEERED TO ELEVATE YOUR PROTOCOL.
A biocompatible1 antimicrobial wound gel that helps manage wounds by maintaining a moist environment—critical to wound progression. While in place, it prevents microbial growth within the gel2, delivering broad-spectrum efficacy3 without interfering with most dressings.
  • Improve workflow, no saline rinse required.
  • Rinse away debris and microorganisms from wounds using a patented combination of ingredients.
Maintains a moist wound environment
Inhibits microbial growth within the gel
Complements most any standard of care
Indicated for a range of wounds, including pressure ulcers (Stage I–IV), diabetic foot and leg ulcers, partial- and full-thickness wounds, post-surgical wounds, first- and second-degree burns, and grafted/donor sites.   View brochure View IFU View how to apply video View how to apply brochure
  1. Biocompatibility evaluated per ISO 10993-1; Data on file: TR-01-23-003
  2. Tested in accordance with USP <51>; Data on file: TR-07-20-003
  3. Data on file: TR-03-16-006

Contact Us

    Global Company Committed to Change

    Next Science, LLC

    10550 Deerwood Park Blvd #300

    Jacksonville, FL 32256

    General Inquiries

    USA +1 855 564 2762

    [email protected]

    NXS Limited

    Level 14, Australia Square,

    264-278 George Street,

    Sydney NSW 2000

    Investor Inquiries

    AUS +61 412 292 977

    [email protected]

    Partnering Inquiries

    [email protected]

    PR-1171-v1
    Terms of Use      Privacy Policy      Cookie Policy
    DME Patient Information
    Client Concerns – Grievances – Compliant Handling      Client Bill of Rights and Responsibilities

    Copyright 2021-25 Next Science. All Rights Reserved.